| Name | Compounded NAD+ (Nicotinamide Adenine Dinucleotide) Therapy |
| Uses | Supports cellular energy production, cognitive function, anti-aging, detoxification, and overall wellness. |
| Route Of Administration | Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Oral (capsules, lozenges). |
| Frequency Of Use | IV: 1-2 times per week; IM: 1-3 times per week; SC: Daily or as recommended; Oral: Daily. |
| Concentration(s) | IV: 100 mg/mL - 500 mg/mL; IM/SC: 50 mg/mL - 200 mg/mL; Oral: 250 mg - 500 mg per dose. |
| Maximum Dosage (Day, Wk) | IV: Max 1,000 mg per session, up to 2 times per week; IM/SC: Max 300 mg per injection, up to 3 times per week; Oral: Max 1,000 mg per day. |
| Contraindications | Active cancer, severe kidney or liver disease, hypotension, allergy to NAD+ or formulation excipients. |
| Possible Side Effects | Common: flushing, nausea, headache, fatigue. Rare: hypotension, dizziness, chest discomfort. |
| Compatibility With Other Treatments/Drugs | Safe with most IV therapies; avoid concurrent high-dose niacin or antihypertensive medications without provider review. |
| Allergies | Check for hypersensitivity to NAD+ or any preservatives in compounded formulations. |
| Administration Time | IV: 1-4 hour infusion depending on dosage; IM/SC: Quick injection; Oral: With or without food, as directed. |
| Dosing/Settings | IV: Start with 250-500 mg per session and titrate based on tolerance; IM/SC: 50-300 mg per session; Oral: 250-500 mg daily. |
| Test Spot Requirement | Not required for NAD+ therapy. |
| Pre-Treatment Guidelines | Ensure adequate hydration, review GFE for patient eligibility, assess for blood pressure sensitivity. |
| Provider Clearance Guidelines | NP, PA, MD, or DO must approve; review patient history of hypotension, cardiac conditions, or prior NAD+ therapy experience. |
| Pre-Treatment Screening Workflow | 1. Check for history of low blood pressure or cardiac issues. 2. Assess liver/kidney function. 3. Confirm patient is well-hydrated. |
| What To Do If Adverse Reaction Occurs | For mild flushing or nausea: slow infusion rate, provide hydration. For severe reactions: discontinue, administer oxygen, monitor vitals, escalate if needed. |
| Clinic Implementation Guidelines | Ensure proper IV/IM/SC preparation, document batch and lot number for compounded doses, follow aseptic technique. |
| Photographic Documentation Protocol | Not required for NAD+ therapy. |
| Post-Treatment Care | Encourage hydration, monitor for delayed reactions, schedule follow-ups for efficacy assessment. |
| Additional Documentation Requirements | Signed informed consent, treatment logs, adverse reaction documentation if applicable. |